Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: Haim R. Branisteanu who wrote (44695)	1/4/2009 9:48:52 AM
From: elmatador	Respond to of 217556

Drug stocks: Teva Pharmaceutical completes acquisition of Barr Pharmaceuticals - Quick Facts 12/23/2008 9:56 AM ET "Femcon Fe is the first and only FDA-approved chewable combination birth control pill that, when taken everyday, can help prevent pregnancy." It just started climbing and Teva goes there and completes acquisition. Barr Pharmaceuticals Inc. Is Climbing On Settlement News 12/22/2008 5:14 PM ET Warner Chilcott, Barr Pharma Settle Femcon Fe Patent Suit (RTTNews) - Barr Pharmaceuticals Inc. (BRL: News ) and Warner Chilcott Company announced after the bell Monday that they entered into a Settlement and License Agreement to resolve the pending patent litigation involving Warner Chilcott's oral contraceptive product, Femcon Fe. Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately 7 years earlier than the expiration of the Warner Chilcott patent. Barr is now trading higher by 0.98 on 7.7 million shares. Barr Pharmaceuticals dipped slightly at the open Monday and fell further in the final hour of trade. The stock closed down by 1.19 at $65.80 on strong volume. by RTT Staff Writer